ENXTPA:SANPharmaceuticals
A Look At Sanofi (ENXTPA:SAN) Valuation After Strong Q1 2026 Results And Key Drug Milestones
Why Sanofi stock is back in focus
Sanofi (ENXTPA:SAN) is drawing fresh attention after reporting first quarter 2026 results with higher sales, strong contributions from newer drug launches, and several important regulatory milestones across neurology, immunology, and diabetes.
See our latest analysis for Sanofi.
Despite a busy few weeks that included Q1 2026 earnings, multiple drug approvals and an offering of €2.3b in new notes, Sanofi’s 30 day share price return of 3.77% and 1 year total...